BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA and its partner Mapp Biopharmaceutical Inc. will explore the potential of a new monoclonal antibody (mAb) based therapeutic for Botulinum Neurotoxin...
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure June 11, 2019 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and...
Public Release
MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure September 28, 2018 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded a contract (HHSO100201800024C) of $14.8 million with options for...